| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6170238 | The Breast | 2013 | 7 Pages |
Abstract
Response monitoring with PET/CT during NAC in breast cancer seems feasible, but is dependent on the breast cancer subtype. PET/CT may predict response in ER-positive/HER2-negative and triple negative tumors, but seems less accurate in HER2-positive tumors.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Bas B. Koolen, Kenneth E. Pengel, Jelle Wesseling, Wouter V. Vogel, Marie-Jeanne T.F.D. Vrancken Peeters, Andrew D. Vincent, Kenneth G.A. Gilhuijs, Sjoerd Rodenhuis, Emiel J.Th. Rutgers, Renato A. Valdés Olmos,